ICH (2005) ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. CPMP/ICH/2/04 http://www.emea.eu.int/pdfs/human/ich/000204en.pdf:Accessed 23 November 2023

ICH (2005) ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CPMP/ICHhttp://www.emea.eu.int/pdfs/human/ich/042302en.pdf:Accessed 23 November 2023

ICH (2000) ICH Topic S7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00 https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-7-safety-pharmacology-studies-human-pharmaceuticals-step-5_en.pdf:Accessed 23 November 2023

ICH (2022) ICH E14/S7B Q&As. Clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential - Questions and answers. https://database.ich.org/sites/default/files/E14-S7B_QAs_Step4_2022_0221.pdf Accessed 4 January 2025

Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H (2012) The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther 91(2):281–288. https://doi.org/10.1038/clpt.2011.224

Article  CAS  PubMed  Google Scholar 

Strauss DG, Wu WW, Li Z, Koerner J, Garnett C (2021) Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14/S7B Updates). Clin Pharmacol Ther 109(2):319–333. https://doi.org/10.1002/cpt.2137

Article  PubMed  PubMed Central  Google Scholar 

Avila AM, Bebenek I, Bonzo JA, Bourcier T, Davis Bruno KL, Carlson DB, Dubinion J, Elayan I, Harrouk W, Lee SL, Mendrick DL, Merrill JC, Peretz J, Place E, Saulnier M, Wange RL, Yao J, Zhao D, Brown PC (2020) An FDA/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol 114:104662. https://doi.org/10.1016/j.yrtph.2020.104662

Article  CAS  PubMed  Google Scholar 

Dessertenne F (1966) [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 59(2):263–272

CAS  PubMed  Google Scholar 

Viskin S, Chorin E, Viskin D, Hochstadt A, Schwartz AL, Rosso R (2021) Polymorphic ventricular tachycardia: terminology, mechanism, diagnosis, and emergency therapy. Circulation 144(10):823–839. https://doi.org/10.1161/CIRCULATIONAHA.121.055783

Article  CAS  PubMed  Google Scholar 

Valentin JP, Hoffmann P, Ortemann-Renon C, Koerner J, Pierson J, Gintant G, Willard J, Garnett C, Skinner M, Vargas HM, Wisialowski T, Pugsley MK (2022) The challenges of predicting Drug-Induced QTc prolongation in humans. Toxicol Sci 187(1):3–24. https://doi.org/10.1093/toxsci/kfac013

Article  CAS  PubMed  PubMed Central  Google Scholar 

CPMP (1997) Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. European Agency for the Evaluation of Medicinal Products. Accessed 14 January 2025

Bialecki RA, Gallacher DJ, Valentin J-P (2024) Drug-Induced QT Prolongation. In: McQueen C (ed) Reference Module in Biomedical Sciences. Elsevier. https://doi.org/10.1016/B978-0-323-95488-4.00070-X

Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP (2010) An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159(1):12–21. https://doi.org/10.1111/j.1476-5381.2009.00207.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

PharmaPendium (2024) Last update December 18, 2024 Edn. Elsevier, Amsterdam, Netherlands

Google Scholar 

Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA (1996) Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit purkinje fibres. Br J Pharmacol 117(7):1377–1379. https://doi.org/10.1111/j.1476-5381.1996.tb15295.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, Richard S (2005) Prediction of the risk of torsade de pointes using the model of isolated canine purkinje fibres. Br J Pharmacol 144(3):376–385. https://doi.org/10.1038/sj.bjp.0706070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2005) Nonclinical proarrhythmia models: predicting Torsades de pointes. J Pharmacol Toxicol Methods 52(1):46–59. https://doi.org/10.1016/j.vascn.2005.04.011

Article  CAS  PubMed  Google Scholar 

Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2008) In vitro models of proarrhythmia. Br J Pharmacol 154(7):1516–1522. https://doi.org/10.1038/bjp.2008.195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beattie KA, Luscombe C, Williams G, Munoz-Muriedas J, Gavaghan DJ, Cui Y, Mirams GR (2013) Evaluation of an in Silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods 68(1):88–96. https://doi.org/10.1016/j.vascn.2013.04.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D (2011) Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical Torsadogenic risk. Cardiovasc Res 91(1):53–61. https://doi.org/10.1093/cvr/cvr044

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L (2004) Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 49(3):171–181. https://doi.org/10.1016/j.vascn.2004.03.008

Article  CAS  PubMed  Google Scholar 

Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Borggrefe M, Breithardt G (1998) Drug-related Torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin. J Cardiovasc Pharmacol 32(3):425–434. https://doi.org/10.1097/00005344-199809000-00013

Article  CAS  PubMed  Google Scholar 

Stockbridge N, Throckmorton DC (2004) Regulatory advice on evaluation of the proarrhythmic potential of drugs. J Electrocardiol 37 Suppl:40–41. https://doi.org/10.1016/j.jelectrocard.2004.08.007

Article  PubMed  Google Scholar 

Cavero I, Holzgrefe H (2015) CiPA: ongoing testing, future qualification procedures, and pending issues. J Pharmacol Toxicol Methods 76:27–37. https://doi.org/10.1016/j.vascn.2015.06.004

Article  CAS  PubMed  Google Scholar 

Gintant G, Sager PT, Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15(7):457–471. https://doi.org/10.1038/nrd.2015.34

Article  CAS  PubMed  Google Scholar 

Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, Quinidine, Ranolazine, and verapamil. Clin Pharmacol Ther 96(5):549–558. https://doi.org/10.1038/clpt.2014.155

Article  CAS  PubMed  Google Scholar 

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. https://doi.org/10.1016/j.cell.2007.11.019

Article  CAS  PubMed  Google Scholar 

Schmid C, Abi-Gerges N, Leitner MG, Zellner D, Rast G (2021) Ion channel expression and electrophysiology of singular human (Primary and induced pluripotent stem Cell-Derived). Cardiomyocytes Cells 10(12). https://doi.org/10.3390/cells10123370

Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P, Mow T, Oinonen T, Roth A, Steger-Hartmann T, Valentin JP, Van Goethem F, Weaver RJ, Newham P (2023) The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov 22(4):317–335. https://doi.org/10.1038/s41573-022-00633-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda Y, Yamazaki D, Kurokawa J, Inutsuka T, Sekino Y (2016) Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system. J Pharmacol Toxicol Methods 81:196–200. https://doi.org/10.1016/j.vascn.2016.06.007

Article  CAS  PubMed  Google Scholar 

Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K (2018) Development of Torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS cardiac safety assessment (JiCSA) update. J Pharmacol Sci 138(4):233–239. https://doi.org/10.1016/j.jphs.2018.10.010

Article  CAS  PubMed  Google Scholar 

Vargas HM, Rolf MG, Wisialowski TA, Achanzar W, Bahinski A, Bass A, Benson CT, Chaudhary KW, Couvreur N, Dota C, Engwall MJ, Michael Foley C, Gallacher D, Greiter-Wilke A, Guillon JM, Guth B, Himmel HM, Hegele-Hartung C, Ito M, Jenkinson S, Chiba K, Lagrutta A, Levesque P, Martel E, Okai Y, Peri R, Pointon A, Qu Y, Teisman A, Traebert M, Yoshinaga T, Gintant GA, Leishman DJ, Valentin JP (2021) Time for a fully integrated Nonclinical-Clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective. Clin Pharmacol Ther 109(2):310–318.